HANIXOL

This brand name is authorized in Ireland, UK.

Active ingredients

The drug HANIXOL contains one active pharmaceutical ingredient (API):

1	Mercaptopurine UNII E7WED276I5 - MERCAPTOPURINE
	Mercaptopurine is an inactive pro-drug which acts as a purine antagonist but requires cellular uptake and intracellular anabolism to thioguanine nucleotides for cytotoxicity. The mercaptopurine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions. The thioguanine nucleotides are also incorporated into nucleic acids and this contributes to the cytotoxic effects of the active substance.
	Read more about Mercaptopurine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HANIXOL Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BB02	Mercaptopurine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues
Discover more medicines within L01BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	375722